A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors
about
A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessmentCardiovascular toxicity profiles of vascular-disrupting agents.Indole molecules as inhibitors of tubulin polymerization: potential new anticancer agents.Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent.A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors.
P2860
A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A dose escalation, safety, and ...... nts with advanced solid tumors
@ast
A dose escalation, safety, and ...... nts with advanced solid tumors
@en
A dose escalation, safety, and ...... nts with advanced solid tumors
@nl
type
label
A dose escalation, safety, and ...... nts with advanced solid tumors
@ast
A dose escalation, safety, and ...... nts with advanced solid tumors
@en
A dose escalation, safety, and ...... nts with advanced solid tumors
@nl
prefLabel
A dose escalation, safety, and ...... nts with advanced solid tumors
@ast
A dose escalation, safety, and ...... nts with advanced solid tumors
@en
A dose escalation, safety, and ...... nts with advanced solid tumors
@nl
P2093
P2860
P1476
A dose escalation, safety, and ...... nts with advanced solid tumors
@en
P2093
Anne M Traynor
David S Mendelson
Dona Alberti
Mark S Munsey
Michael S Gordon
Richard E Gammans
William L Read
P2860
P2888
P304
P356
10.1007/S10637-009-9264-2
P577
2009-05-13T00:00:00Z
P5875
P6179
1044552894